The radiation biology of boron neutron capture therapy

Radiation Research

Volumn 151, Issue 1, 1999, Pages 1-18

  Coderre, Jeffrey A ^a   Morris, Gerard M ^b  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 BORONOPHENYLALANINE; BORNANE DERIVATIVE;

HUMAN; LINEAR ENERGY TRANSFER; NEUTRON CAPTURE THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION HAZARD; RADIATION INJURY; RADIATION PHYSICS; RADIOBIOLOGY; REVIEW; RISK ASSESSMENT; SKIN INJURY; SPINAL CORD INJURY;

ANIMALS; BORON NEUTRON CAPTURE THERAPY; HUMANS; LINEAR ENERGY TRANSFER; RADIOBIOLOGY; RATS;

EID: 0032939720     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.2307/3579742     Document Type: Review

References (126)

1. G. L. Locher, Biological effects and therapeutic possibilities of neutrons. Am. J. Roentgenol. 36, 1-13 (1936).
2. H. J. Taylor and M. Goldhaber, Detection of nuclear disintegration in a photographic emulsion. Nature 135, 341 (1935).
3. D. N. Slatkin, A history of boron neutron capture therapy of brain tumours - Postulation of a brain radiation dose tolerance limit. Brain 114, 1609-1629 (1991).
4. A. K. Asbury, R. G. Ojeman, S. L. Nielsen and W. H. Sweet, Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture therapy. J. Neuropathol. Exp. Neurol. 31, 278-303 (1972).
5. H. Hatanaka, Clinical experience of boron-neutron capture therapy for gliomas - A comparison with conventional chemo-immuno-radiotherapy. In Boron-Neutron Capture Therapy for Tumors (H. Hatanaka, Ed.), pp. 349-379. Nishimura Co. Ltd., Niigata, 1986.
6. H. Hatanaka and Y. Nakagawa, Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28, 1061-1066 (1994).
7. Y. Nakagawa and H. Hatanaka, Boron neutron capture therapy: Clinical brain tumor studies. J. Neuro-Oncol. 33, 105-115 (1997).
8. G. E. Laramore and A. M. Spence, Boron neutron-capture therapy (BNCT) for high-grade gliomas of the brain - A cautionary note. Int. J. Radiat. Oncol. Biol. Phys. 36, 241-246 (1996).
9. J. A. Coderre, E. E. Elowitz, M. Chadha, R. Bergland, J. Capala, D. D. Joel, H. B. Liu, D. N. Slatkin and A. D. Chanana, Boron neutron capture therapy of glioblastoma multiforme using the p-boronophenylalanine-fructose complex and epithermal neutrons: Trial design and early clinical results. J. Neuro-Oncol. 33, 141-152 (1997).
10. H. Madoc-Jones, R. Zamenhof, G. Solares, O. Harling, C-S. Yam, K. Riley, S. Kiger, D. Wazer, G. Rogers and M. Atkins, A Phase-I dose escalation trial of boron neutron capture therapy for subjects with metastatic subcutaneous melanoma of the extremities. In Cancer Neutron Capture Therapy (Y. Mishima, Ed.), pp. 707-716. Plenum Press, New York, 1996.
11. R. F. Barth, A. H. Soloway, R. G. Fairchild and R. M. Brugger, Boron neutron capture therapy for cancer. Realities and prospects. Cancer 70, 2995-3007 (1992).
12. R. F. Barth, A. H. Soloway and R. M. Brugger, Boron neutron-capture therapy of brain-tumors - past history, current status, and future potential. Cancer Invest. 14, 534-550 (1996).
13. J. A. Coderre, Boron neutron capture therapy. In Textbook of Radiation Oncology (S. Leibel and T. Phillips, Eds.), pp. 1263-1277. W. B. Saunders, Philadelphia, 1998.
14. M. F. Hawthorne, The role of chemistry in the development of boron neutron capture therapy of cancer. Angew. Chem. Int. Ed. 32, 950-984 (1993).
15. A. H. Soloway, W. Tjarks, B. A. Barnum, F-G. Rong, R. F. Barth, I. M. Codogni and J. G. Wilson, The chemistry of neutron capture therapy. Chem. Rev. 98, 1515-1562 (1998).
16. R. L. Moss, O. Aizawa, D. Beynon, R. Brugger, G. Constantine, O. Harling, H. B. Liu and P. Watkins, The requirements and development of neutron beams for neutron capture therapy of brain cancer. J. Neuro-Oncol. 33, 27-40 (1997).
17. H. R. Snyder, A. H. Reedy and W. Lennarz, Synthesis of aromatic boronic acids. Aldehydo boronic acids and a boronic acid analog of tyrosine. J. Am. Chem. Soc. 80, 835-838 (1958).
18. 10B/melanogenesis interaction to in vitrolin vivo radiobiological analysis to preclinical studies. In Proceedings of the First International Symposium on Neutron Capture Therapy (R. G. Fairchild and G. Brownell, Eds.), pp. 355-364. Brookhaven National Laboratory, Upton, NY, 1983.
19. R. F. Barth, K. Z. Matalka, M. Q. Bailey, A. E. Staubus, A. H. Soloway, M. L. Moeschberger, J. A. Coderre and E. K. Rofstad, A nude rat model for neutron capture therapy of human intracerebral melanoma. Int. J. Radiat. Oncol. Biol. Phys. 28, 1079-1088 (1994).
20. J. A. Coderre, D. N. Slatkin, P. L. Micca and J. R. Ciallella, Boron neutron capture therapy of a murine melanoma with p-boronophenylalanine: Dose-response analysis using a morbidity index. Radiat. Res. 128, 177-185 (1991).
21. J. A. Coderre, S. G. Packer, D. Greenberg, P. L. Micca, D. D. Joel and S. Saraf, Boron neutron capture therapy of ocular melanoma and intracranial glioma using p-boronophenylalanine. In Progress in Neutron Capture Therapy for Cancer (B. J. Allen, D. E. Moore and B. V. Harrington, Eds.), pp. 463-468. Plenum Press, New York, 1992.
22. K. Z. Matalka, M. Q. Bailey, R. F. Barth, A. E. Staubus, A. H. Soloway, M. L. Moeschberger, J. A. Coderre and E. K. Rofstad, Boron neutron capture therapy of intracerebral melanoma using boronophenylalanine as a capture agent. Cancer. Res. 53, 3308-3313 (1993).
23. Y. Mishima, M. Ichihashi, C. Honda, M. Shiono, T. Nakagawa, H. Obara, J. Shirakawa, J. Hiratsuka, K. Kanda, T. Kobayashi, T. Nozaki, O. Aizawa, T. Sato, H. Karashima, K. Yoshino and H. Fukuda, Advances in the control of cutaneous primary and metastatic melanoma by thermal neutron capture therapy. In Progress in Neutron Capture Therapy for Cancer (B. J. Allen, D. E. Moore and B. V. Harrington, Eds.), pp. 577-583. Plenum Press, New York, 1992.
24. 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the skin. Radiat. Res. 138, 435-442 (1994).
25. H. Fukuda, Y. Mishima, J. Hiratsuka, C. Honda, N. Wadabayayashi, T. Kobayashi, K. Yoshino, H. K. Takahashi, Y. Abe, K. Kanda and M. Ichihashi, BNCT of malignant melanoma: Radiobiological analysis and data comparison with conventional radiotherapy. In Cancer Neutron Capture Therapy (Y. Mishima, Ed.), pp. 663-671. Plenum Press, New York, 1996.
26. J. A. Coderre, J. D. Glass, R. G. Fairchild, P. L. Micca, I. Fand and D. D. Joel, Selective delivery of boron by the melanin precursor analog p-boronophenylalanine to tumors other than melanoma. Cancer Res. 50, 138-141 (1990).
27. J. A. Coderre, D. D. Joel, P. L. Micca, M. M. Nawrocky and D. N. Slatkin, Control of intracerebral gliosarcomas in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat. Res. 129, 290-296 (1992).
28. J. A. Coderre, T. M. Button, P. L. Micca, C. D. Fisher, M. M. Nawrocky and H. B. Liu, Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex. Int. J. Radiat. Oncol. Biol. Phys. 30, 643-652 (1994).
29. J. A. Coderre, J. D. Glass, R. G. Fairchild, U. Roy, S. Cohen and I. Fand, Selective targeting of boronophenylalanine to melanoma for neutron capture therapy. Cancer Res. 47, 6377-6383 (1987).
30. J. A. Coderre, A Phase 1 biodistribution study of p-boronophenylalanine. In Boron Neutron Capture Therapy: Towards Clinical Trials of Glioma with BNCT (R. Moss and D. Gabel, Eds.), pp. 111-121. Plenum Press, New York, 1992.
31. J. A. Coderre, A. D. Chanana, D. D. Joel, E. H. Elowitz, P. L. Micca, M. M. Nawrocky, M. Chadha, J-O. Gebbers, M. Shady, N. S. Peress and D. N. Slatkin, Biodistribution of boronophenylalanine in patients with glioblastoma multiforme: Boron concentration correlates with tumor cellularity. Radiat. Res. 149, 163-170 (1998).
32. D. N. Slatkin, M. M. Nawrocky, J. A. Coderre, C. D. Fisher, D. D. Joel, D. T. Lombardo and P. L. Micca, Boron concentrations in rat tissues after partial hepatectomy and a single injection of L-BPA/ fructose complex. In Advances in Neutron Capture Therapy (B. Larsson, J. Crawford and R. Weinreich, Eds.), pp. 229-233. Elsevier, Amsterdam, 1997.
33. 18F-DOPA analogue. J. Neuro-Oncol. 33, 163-169 (1997).
34. G. W. Kabalka, G. T. Smith, J. P. Dyke, W. S. Reid, C. P. D. Longford, T. G. Roberts, N. K. Reddy, E. Buonocore and K. F. Hubner, Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning. J. Nucl. Med. 38, 1762-1767 (1997).
35. Y. Imahori, S. Ueda, Y. Ohmori, T. Kusuki, K. Ono, R. Fujii and T. Ido, Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J. Nucl. Med. 39, 325-333 (1998).
36. B. D. Bennett, X. H. Zha, I. Gay and G. H. Morrison, Intracellular boron localization and uptake in cell cultures using imaging secondary ion mass spectrometry (ion microscopy) for neutron capture therapy for cancer. Biol. Cell. 74, 105-108 (1992).
37. B. D. Bennett, J. Mumford-Zisk, J. A. Coderre and G. H. Morrison, Subcellular localization of p-boronophenylalanine-delivered boron-10 in the rat 9L gliosarcoma: Cryogenic preparation in vitro and in vivo. Radiat. Res. 140, 72-78 (1994).
38. S. Chandra, D. R. Lorey, S. L. Lessig, D. R. Smith and G. H. Morrison, Quantitative imaging of boron from BPA and BSH in glioblastoma cells with ion microscopy. In Advances in Neutron Capture Therapy. Volume II, Chemistry and Biology (B. Larsson, J. Crawford and R. Weinreich, Eds.), pp. 315-320. Elsevier, Lausanne, 1997.
39. 10B from p-boronophenylalanine in a brain tumor model for boron neutron capture therapy. Cancer Res. 56, 4302-4306 (1996).
40. D. R. Smith, S. Chandra, J. A. Coderre, R. F. Barth, W. Yang, L. Liu, J. L. Wilson, P. L. Micca, M. M. Nawrocky, J. H. Rotaru and G. H. Morrison, Quantitative ion microscopy imaging of boron-10 in rat brain tumor models for BNCT. In Advances in Neutron Capture Therapy. Volume II, Chemistry and Biology (B. Larsson, J. Crawford and R. Weinreich, Eds.), pp. 308-314. Elsevier, Lausanne, 1997.
41. A. L. Soloway, R. L. Wright and J. R. Messer, Evaluation of boron compounds for use in neutron capture therapy of brain tumors. 1. Animal investigations. J. Pharmacol. Exp. Therapeut. 134, 117-122 (1961).
42. A. H. Soloway, H. Hatanaka and M. A. Davis, Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J. Med. Chem. 10, 714-717 (1967).
43. W. F. Bauer, K. N. Bradshaw and T. L. Richards, Interaction between boron containing compounds and serum albumin observed by nuclear magnetic resonance. In Progress in Neutron Capture Therapy for Cancer (B. J. Allen and B. V. Harrington, Eds.), pp. 339-343. Plenum Press, New York, 1992.
44. S. L. Kraft, P. R. Gavin, C. E. DeHaan, C. W. Leathers, W. F. Bauer, D. L. Miller and R. V. Dorn, Borocaptate sodium - A potential boron delivery compound for boron neutron capture therapy evaluated in dogs with spontaneous intracranial tumors. Proc. Natl. Acad. Sci. USA 89, 11973-11977 (1992).
45. R. F. Barth, W. Yang, J. H. Rotaru, M. L. Moeschberger, D. D. Joel, M. M. Nawrocky, J. H. Goodman and A. H. Soloway, Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 57, 1129-1136 (1997).
46. D. D. Joel, D. N. Slatkin, R. G. Fairchild, P. Micca and M. Nawrocky, Pharmacokinetics and tissue distribution of the sulfhydryl boranes (monomer and dimer) in glioma-bearing rats. Strahlenther. Onkol. 165, 167-170 (1989).
47. C. P. Ceberg, A. Brun, S. B. Kahl, M. S. Koo, B. R. R. Persson and L. G. Salford, A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J. Neurosurg. 83, 86-92 (1995).
48. 11SH (BSH) in patients with malignant brain tumours as prerequisite for a Phase I clinical trial of boron neutron capture. Acta Neurochir. 139, 606-612 (1997).
49. 11SH into a patient with malignant astrocytoma: Implications for boron neutron capture therapy. Neurosurgery 24, 6-11 (1989).
50. 11SH, at subcellular resolution in tissue cultures using ion microscopy. Cancer Res. 52, 5219-5222 (1992).
51. 11SH on cellular and subcellular level in tumor tissue of glioma patients in boron neutron capture therapy. J. Neuro-Oncol. 33, 131-139 (1997).
52. 11SH. J. Neurosurg. 8, 741-744 (1994).
53. D. A. Feakes, K. Shelly and M. F. Hawthorne, Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc. Natl. Acad. Sci. USA 92, 1367-1370 (1995).
54. K. Shelly, E. M. Georgiev, R. Watson-Clark and M. F. Hawthorne, Boron delivery to tumors for BNCT: Recent murine results with liposomes. In Advances in Neutron Capture Therapy: Volume II, Chemistry and Biology (B. Larsson, J. Crawford and R. Weinreich, Eds.), pp. 357-361. Elsevier, Lausanne, 1997.
55. M. Miura, P. L. Micca, C. D. Fisher, J. C. Heinrichs, J. A. Donaldson, G. C. Finkel and D. N. Slatkin, Synthesis of a nickel tetracarboranylphenylporphyrin for boron neutron-capture therapy - biodistribution and toxicity in tumor-bearing mice. Int. J. Cancer 68, 114-119 (1996).
56. R. G. Fairchild, "Epithermal" neutron beam isodose charts in a phantom head. Radiology 85, 555-564 (1965).
57. H. Liu, R. Brugger and D. Rorer, Enhancement of the epithermal neutron beam at the Brookhaven Medical Research Reactor. In Advances in Neutron Capture Therapy (A. H. Soloway, R. F. Barth and D. E. Carpenter, Eds.), pp. 75-79. Plenum Press, New York, 1993.
58. D. W. Nigg, Methods for radiation dose distribution analysis and treatment planning in boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28, 1121-1134 (1994).
59. D. W. Nigg, F. J. Wheeler, D. E. Wessol, J. Capala and M. Chadha, Computational dosimetry and treatment planning for boron neutron capture therapy. J. Neuro-Oncol. 33, 93-103 (1997).
60. 10B boron neutron capture therapy: Enhancement of tumor dose via beam filtration and dose rate, and the effects of these parameters on minimum boron content: A theoretical evaluation. Int. J. Radiat. Oncol. Biol. Phys. 11, 831-840 (1985).
61. T. Kobayashi and K. Kanda, Analytical calculation of boron-10 dosage in cell nucleus for neutron capture therapy. Radiat. Res. 91, 77-94 (1982).
62. 7Li reaction in cells and tissue and its implication for boron neutron capture therapy. Radiat. Res. 111, 14-25 (1987).
63. H. I. Amols and L. E. Reinstein, Stochastic considerations in BNCT; Microdosimetry and cell survival. In Topics in Dosimetry and Treatment Planning for Neutron Capture Therapy (R. Zamenhof, G. Solares and O. Harling, Eds.), pp. 1-12. Advanced Medical Publishing, Madison, WI, 1994.
64. R. Verrijk, R. Huiskamp, A. C. Begg, F. J. Wheeler and P. R. D. Watkins, A comprehensive PC-based computer model for microdosimetry of BNCT. Int. J. Radiat. Biol. 65, 241-253 (1994).
65. R. Gahbauer, R. G. Fairchild, J. H. Goodman and T. E. Blue, RBE in normal tissue studies. In Towards Clinical Trials of Glioma Treatment (D. Gabel and R. L. Moss, Eds.), pp. 123-128. Plenum Press, New York, 1992.
66. G. M. Morris, J. A. Coderre, J. W. Hopewell, P. L. Micca and M. Rezvani, Response of rat skin to boron neutron capture therapy with p-boronophenylalanine or borocaptate sodium. Radiother. Oncol. 32, 144-153 (1994).
67. 7Li reaction in HeLa cells. Radiat. Res. 43, 534-553 (1970).
68. 7Li reaction on cultured B-16 melanoma cells. Int. J. Radiat. Biol. 51, 167-175 (1987).
69. D. Gabel, R. G. Fairchild and B. Larsson, The relative biological effectiveness in V79 Chinese hamster cells of the neutron capture reaction in boron and nitrogen. Radiat. Res. 98, 307-316 (1984).
70. J. A. Coderre and M. A. Makar, Radiobiology of boron neutron capture therapy: problems with the concept of relative biological effectiveness. In Progress in Neutron Capture Therapy for Cancer (B. Allen, D. Moore and B. Harrington, Eds.), pp. 463-468. Plenum Press, New York, 1992.
71. 7Li RBE for the 9L rat gliosarcoma in vitro and in vivo. In Topics in Dosimetry and Treatment Planning for Boron Neutron Capture Therapy (R. G. Zamenhof, G. Solares and O. Harling, Eds.), pp. 37-47. Advanced Medical Publishing, Madison, WI, 1994.
72. J. A. Coderre, M. S. Makar, P. L. Micca, M. M. Nawrocky, H. B. Liu, D. D. Joel, D. N. Slatkin and H. I. Amols, Derivations of relative biological effectiveness for the high-LET radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 27, 1121-1129 (1993).
73. J. Capala, M. S. Makar and J. A. Coderre, Accumulation of boron in malignant and normal cells incubated in vitro with boronophenylalanine, mercaptoborane or boric acid. Radiat. Res. 146, 554-560 (1996).
74. B. G. Douglas, Implication of the quadratic cell survival curve and human skin radiation "tolerance dose" on fractionation and super-fractionation dose selection. Int. J. Radiat. Oncol. Biol. Phys. 8, 1135-1142 (1982).
75. L. Cohen, Radiation response and recovery: Radiobiological principles and their relation to clinical practice. In The Biological Basis of Radiation Therapy (E. E. Schwartz, Ed.), p. 248. J. B. Lippincott, Philadelphia, 1966.
76. 7Li reaction on the skin of man. Radiology 94, 179-187 (1970).
77. 7Li reaction for the rabbits ear and its utilization for neutron capture therapy. Yokohama Med. Bull. 12, 4-22 (1961).
78. 10B-neutron capture therapy for early skin reaction in the hamster. Radiat. Res. 128, 186-191 (1991).
79. P. R. Gavin, F. J. Wheeler, R. Huiskamp, A. Siefert, S. Kraft and C. DeHaan, Large animal studies of normal tissue tolerance using an epithermal neutron beam and borocaptate sodium. In Towards Clinical Trials of Glioma (D. Gabel and R. Moss, Eds.), pp. 197-209. Plenum Press, New York, 1992.
80. J. W. Hopewell and E. A. Wright, The nature of latent cerebral irradiation damage and its modification by radiation damage. Br. J. Radiol. 43, 161-167 (1970).
81. J. W. Hopewell, Late radiation damage to the central nervous system. A radiobiological interpretation. Neuropathol. Appl. Neurobiol. 5, 329-343 (1979).
82. H. S. Reinhold and J. W. Hopewell, Late changes in the architecture of blood vessels of the rat brain after irradiation. Br. J. Radiobiol. 53, 693-696 (1980).
83. W. F. Blakemore and A. C. Palmer, Delayed infarction of spinal cord white matter following X-irradiation. J. Pathol. 137, 273-280 (1982).
84. A. J. van der Kogel, The cellular basis of radiation-induced damage in the central nervous system. In Cytotoxic Insult to Tissues; Effects on Cell Lineages (C. S. Potten and J. H. Hendry, Eds.), pp. 329-352. Churchill-Livingstone, Edinburgh, 1983.
85. R. Meyers, M. A. Rogers and S. Hornsey, A reappraisal of the roles of glial and vascular elements in the development of white matter necrosis in irradiated rat spinal cord. Br. J. Cancer 53 (Suppl. 7), 221-223 (1986).
86. H. R. Withers, J. M. G. Taylor and B. Maciejewski, Treatment volume and tissue tolerance. Int. J. Radiat. Oncol. Biol. Phys. 14, 751-759 (1988).
87. G. M. Morris, J. A. Coderre, A. Bywaters, E. Whitehouse and J. W. Hopewell, Boron neutron capture irradiation of the rat spinal cord: Histopathological evidence of a vascular-mediated pathogenesis. Radiat. Res. 146, 313-320 (1996).
88. A. J. van der Kogel, B. J. Kleiboer, I. Verhagen, G. M. Morris, J. W. Hopewell and J. A. Coderre, White matter necrosis of the spinal cord: Studies on glial progenitor survival and selective vascular irradiation. In Radiation Research 1895-1995, Vol. 2 (U. Hagen, D. Harder, H. Jung and C. Streffer, Eds.), pp. 769-769. Universitätsdruckerei H. Sturtz AG, Würzburg, 1995.
89. R. A. Rydin, O. L. Deutsch and B. W. Murray, The effect of geometry on capillary wall dose for boron neutron capture therapy. Phys. Med. Biol. 21, 134-138 (1976).
90. R. G. Zamenhof, Microdosimetry for boron neutron capture therapy: A review. J. Neuro-Oncol. 33, 81-92 (1997).
91. G. M. Morris, J. A. Coderre, J. W. Hopewell, P. L. Micca, M. M. Nawrocky, H. B. Liu and A. Bywaters, Response of the central nervous system to boron neutron capture irradiation: Evaluation using rat spinal cord model. Radiother Oncol. 32, 249-255 (1994).
92. G. M. Morris, J. A. Coderre, P. L. Micca, C. D. Fisher, J. Capala and J. W. Hopewell, Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine. Br. J. Cancer 76, 1623-1629 (1997).
93. J. A. Coderre, G. M. Morris, P. L. Micca, C. D. Fisher and G. A. Ross, Comparative assessment of single-dose and fractionated boron neutron capture therapy. Radiat. Res. 144, 310-317 (1995).
94. G. M. Morris, J. A. Coderre, E. M. Whitehouse, P. Micca and J. W. Hopewell, Boron neutron capture therapy - A guide to the understanding of the pathogenesis of late radiation damage to the rat spinal cord. Int. J. Radiat. Oncol. Biol. Phys. 28, 1107-1112 (1994).
95. P. R. Gavin, F. J. Wheeler, R. Huiskamp, A. Siefert, S. Kraft and C. DeHaan, Large animal model studies of normal tissue tolerance using an epithermal neutron beam and borocaptate sodium. In Boron Neutron Capture Therapy (D. Gabel and R. Moss, Eds.), pp. 197-209. Plenum Press, New York, 1992.
96. P. R. Gavin, S. L. Kraft, R. Huiskamp and J. A. Coderre, A review: CNS effects and normal tissue tolerance in dogs. J. Neuro-Oncol. 33, 71-80 (1997).
97. A. J. van der Kogel, Central nervous system radiation injury in small animal models. In Radiation Injury to the Nervous System (P. H. Gutin, S. A. Leibel and G. E. Sheline, Eds.), pp. 91-111. Raven Press, New York, 1991.
98. 10B-BPA. In Cancer Neutron Capture Therapy (Y. Mishima, Ed.), pp. 823-827. Plenum Press, New York, 1996.
99. G. M. Morris, J. A. Coderre, J. W. Hopewell, P. L. Micca and C. Fisher, Boron neutron capture irradiation of the rat spinal cord: effects of variable doses of borocaptate sodium. Radiother. Oncol. 39, 253-259 (1996).
100. S. Hornsey, Experimental central nervous system injury from fast neutrons. In Radiation Injury to the Nervous System (P. H. Gutin, S. A. Leibel and G. E. Sheline, Eds.), pp. 137-148. Raven Press, New York, 1991.
101. A. J. van der Kogel, Chronic effects of neutrons and charged particles on spinal cord, lung, and rectum. Radiat. Res. 104, 208-216 (1985).
102. A. J. van der Kogel, H. A. Sissingh and J. Zoetelief, Effect of X-rays and neutrons on repair and regeneration in the rat spinal cord. Int. J. Radiat. Oncol. Biol. Phys. 8, 2095-2097 (1982).
103. R. Huiskamp, P. R. Gavin, J. A. Coderre, K. H. I. Phillip and F. J. Wheeler, Brain tolerance in dogs to boron neutron capture therapy with borocaptate sodium (BSH) or boronophenylalanine (BPA). In Cancer Neutron Capture Therapy (Y. Mishima, Ed.), pp. 591-596. Plenum Press, New York, 1996.
104. 7Li reaction from borocaptate sodium and the relative biological effectiveness of recoil protons for induction of brain damage in boron neutron capture therapy. Radiat. Res. 149, 378-386 (1998).
105. J. R. Fike, C. E. Cann, K. Turowski, R. J. Higgins, A. S. L. Chan, T. L. Phillips and R. L. Davis, Radiation dose response of normal brain. Int. J. Radiat. Oncol. Biol. Phys. 14, 63-70 (1988).
106. L. E. Farr and T. Konikowski, Transplantable mouse neoplasm control by neutron capture therapy. Nature 215, 550-552 (1967).
107. S. Packer, J. Coderre, S. Saraf, R. Fairchild, J. Hansrote and H. Perry, Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine. Invent. Ophthalmol. Vis. Sci. 33, 395-403 (1992).
108. D. D. Joel, R. G. Fairchild, J. A. Laissue, S. K. Saraf, J. A. Kalef-Ezra and D. N. Slatkin, Boron neutron capture therapy of intracerebral rat gliosarcomas. Proc. Natl. Acad. Sci. USA 87, 9808-9812 (1990).
109. S. C. Saris, G. R. Solares, D. E. Wazer, G. Cano, S. E. Kerley, M. A. Joyce, L. S. Adelman, O. K. Harling, H. Madoc-Jones and R. G. Zamenhof, Boron neutron capture therapy for murine malignant gliomas. Cancer Res. 52, 4672-4677 (1992).
110. W. Yang, R. F. Barth, D. E. Carpenter, M. Moeschberger and J. H. Goodman, Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery 38, 985-992 (1996).
111. W. Yang, R. F. Barth, J. H. Rotaru, M. L. Moeschberger, D. D. Joel, M. M. Nawrocky, J. H. Goodman and A. H. Soloway, Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of sodium borocaptate with or without blood brain barrier disruption. Int. J. Radiat. Oncol. Biol. Phys. 37, 663-672 (1997).
112. R. K. Jain, Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50 (Suppl.), S814-S819 (1990).
113. G. M. Morris, J. A. Coderre, J. W. Hopewell, M. Rezvani, P. L. Micca and C. D. Fisher, Response of the central nervous system to fractionated boron neutron capture irradiation: Studies with borocaptate sodium. Int. J. Radiat. Biol. 71, 185-192 (1997).
114. P. R. Gavin, F. J. Wheeler and C. D. Swartz, Fractionation effects of BNCT on normal tissue tolerance of the canine brain. In Advances in Neutron Capture Therapy: Volume II, Chemistry and Biology (B. Larsson, J. Crawford and R. Weinreich, Eds.), pp. 670-675. Elsevier, Lausanne, 1997.
115. R. Zamenhof, E. Redmond, G. Solares, D. Katz, K. Riley, S. Kiger and O. Harling, Monte-Carlo-based treatment planning for boron neutron capture therapy using custom designed models automatically generated from CT data. Int. J. Radial. Oncol. Biol. Phys. 35, 383-397 (1996).
116. E. H. Elowitz, R. M. Bergland, J. A. Coderre, D. D. Joel, M. Chadha and A. D. Chanana, Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy. Neurosurgery 42, 463-469 (1998).
117. M. Chadha, J. Capala, J. A. Coderre, E. H. Elowitz, J-I. Iwai, D. D. Joel, H. B. Liu, L. Wielopolski and A. D. Chanana, Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int. J. Radiat. Oncol. Biol. Phys. 40, 829-834 (1998).
118. J. E. Masciopinto, A. B. Levin, M. P. Mehta and B. S. Rhode, Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J. Neurosurg. 82, 530-535 (1995).
119. J. F. Fowler, The linear quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol. 62, 679-694 (1989).
120. E. J. Hall, Radiobiology for the Radiologist, 3rd ed., pp. 239-259. J. B. Lippincott, Philadelphia, 1988.
121. H. D. Thames and J. H. Hendry, Fractionation in Radiotherapy, pp. 229-230. Taylor & Francis, Philadelphia, 1987.
122. D. Gabel, Radiobiological considerations concerning the development of compounds for boron neutron capture therapy. Strahlenther. Oncol. 169, 65-70 (1993).
123. J. O. Archambeau, Swine skin: A model to evaluate dose recovery from different radiations. In Clinical Aspects of Neutron Capture Therapy (R. G. Fairchild, V. P. Bond and A. D. Woodhead, Eds.), pp. 9-20. Plenum Press, New York, 1989.
124. P. R. Gavin, C. E. DeHaan, M. P. Moore, J. P. Weidner, C. D. Schwartz, S. L. Keaft, C. A. Atkinson, C. R. Amaro, W. F. Bauer and A. Seifert, Large animal studies on the use of BNCT for the treatment of brain tumors. In Advances in Neutron Capture Therapy (A. H. Soloway, R. F. Barth and D. E. Carpenter, Eds.), pp. 469-475. Plenum Press, New York, 1993.
125. C. S. Wong, S. Minkin and R. P. Hill, Linear-quadratic model underestimates sparing effect of small doses per fraction in rat spinal cord. Radiother. Oncol. 23, 176-184 (1992).
126. C. S. Wong, J. K. Poon and R. P. Hill, Re-irradiation tolerance in the rat spinal cord: influence of level of initial damage. Radiother. Oncol. 26, 132-138 (1993).